Market closedNon-fractional

Myriad Genetics/MYGN

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Myriad Genetics

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Ticker

MYGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Salt Lake City, United States

Employees

2,700

Myriad Genetics Metrics

BasicAdvanced
$2.2B
Market cap
-
P/E ratio
-$2.77
EPS
1.97
Beta
-
Dividend rate
$2.2B
1.97
1.987
1.522
17.5
19.316
-39.41%
-6.27%
-29.41%
2.72
2.93
16.87
-13.6
11.44%
53.01%
11.00%
11.98%

What the Analysts think about Myriad Genetics

Analyst Ratings

Majority rating from 12 analysts.
Buy

Myriad Genetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12.85% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$202M
2.85%
Net income
-$26M
-16.67%
Profit margin
-12.85%
-18.98%

Myriad Genetics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 90.47%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.03
$0.04
-$0.01
-
Expected
-$0.09
-$0.08
$0.01
-$0.10
-$0.01
Surprise
-5.88%
-63.01%
214.29%
-90.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Myriad Genetics stock?

Myriad Genetics (MYGN) has a market cap of $2.2B as of July 04, 2024.

What is the P/E ratio for Myriad Genetics stock?

The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of July 04, 2024.

Does Myriad Genetics stock pay dividends?

No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Myriad Genetics dividend payment date?

Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Myriad Genetics?

Myriad Genetics (MYGN) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Myriad Genetics stock

Buy or sell Myriad Genetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing